A Phase II Clinical Study of BBI503 in Asymptomatic Recurrent Ovarian Cancer Patients With CA-125 Elevation
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 15 Mar 2017
At a glance
- Drugs Amcasertib (Primary)
- Indications Fallopian tube cancer; Glandular and epithelial neoplasms; Ovarian cancer; Peritoneal cancer
- Focus Biomarker; Therapeutic Use
- Sponsors Boston Biomedical
- 07 Jun 2017 Biomarkers information updated
- 09 Mar 2017 Status changed from recruiting to active, no longer recruiting.
- 16 Dec 2015 Planned number of patients changed from 25 to 30 as per ClinicalTrials.gov record.